Serenella M. Pupa

Fondazione IRCCS Istituto Nazionale dei Tumori — Italy

Medicine · Health Sciences

40h-index6.3kcitations238works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(85), Monoclonal and Polyclonal Antibodies Research(64), Immunotherapy and Immune Responses(40), CAR-T cell therapy research(40), Gastric Cancer Management and Outcomes(35)

Publications238 total

MiRNAs: a call to arms that shapes the plasticity of tumor associated macrophages in breast cancer
Frontiers in Immunology·2026Open Access
Table S2 from <i>HER2</i> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
2025Open Access
Figure S4 from <i>HER2</i> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
2025Open Access
Figure S5 from <i>HER2</i> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
2025Open Access
Figure S3 from <i>HER2</i> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
2025Open Access
Table S1 from <i>HER2</i> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
2025Open Access
Figure S2 from <i>HER2</i> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
2025Open Access
Supplementary Methods1 from <i>HER2</i> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
2025Open Access
Figure S1 from <i>HER2</i> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
2025Open Access
ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs
Journal of Experimental & Clinical Cancer Research·2025Open Access
Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer
Scientific Reports·2025· 2 citedOpen Access
Small extracellular vesicles: messengers at the service of breast cancer agenda in the primary and distant microenvironments
Journal of Experimental & Clinical Cancer Research·2025· 3 citedOpen Access
Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness
npj Breast Cancer·2025· 2 citedOpen Access
Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
Journal of Experimental & Clinical Cancer Research·2025· 1 citedOpen Access
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer
Molecular Cancer·2025· 15 citedOpen Access
Abstract 1712: CD36 enrichment in HER2+ mesenchymal stem cells potentiates therapy refractoriness in HER2+ breast cancer
Cancer Research·2025
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
Journal of Experimental & Clinical Cancer Research·2025· 11 citedOpen Access
Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution
Cancer Cell International·2024· 9 citedOpen Access
Impact of in vitro SARS-CoV-2 infection on breast cancer cells
Scientific Reports·2024· 2 citedOpen Access
Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings
PLoS ONE·2024· 7 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Sylvie Ménard(29), Elda Tagliabue(22), Lorenzo Castagnoli(14), Manuela Campiglio(9), Massimo Di Nicola(8), Patrizia Nanni(7), Pier‐Luigi Lollini(7), Piero Musiani(6), Patrizia Casalini(6), Filippo de Braud(6), Gaia C. Ghedini(5), Maria I. Colnaghi(5), Emma Di Carlo(5), Manuela Iezzi(5), Roberta Zappasodi(5), Claudio Vernieri(5), Daniele Morelli(4), Stefania Forti(4), Silvana Canevari(4), Carla De Giovanni(4)